Patrick Moriarty

Patrick M. Moriarty, MD

Professor, Department of Internal Medicine

Director, Division of Clinical Pharmacology and

Atherosclerosis/ Lipid Apheresis Center

University of Kansas Medical Center

Kansas City, Kansas

Patrick M. Moriarty, MD is a Professor of Medicine at The University of Kansas Medical

Center in Kansas City, Kansas.  He is the

Director of Clinical Pharmacology and the Atherosclerosis & Lipoprotein-Apheresis

Center.  He earned his Doctorate in Medicine and Surgery at the University of Rome

School of Medicine and Surgery in Italy and completed his residency in Internal Medicine and training in Clinical Pharmacology at the University of Kansas  Medical Center.

Dr. Moriarty is a fellow of the American College of Physicians, the American College of

Cardiology, and the National Lipid Association.  He is the past president of the International Society for Apheresis and serves as a manuscript reviewer for multiple scientific journals and is the associate editor for The Journal of Clinical Apheresis and Clinical Lipidology. Member of the scientific advisory board for the FH Foundation. Authored or co-authored over 100 articles, abstracts and  chapters in peer review journals.

Research activities include atherosclerosis, FH, Lp(a), Lipoprotein-Apheresis, vascular  Inflammation, dementia and hemo-rheology.  He has participated in numerous clinical trials related to dyslipidemia, Lp(a), obesity, hypertension, and diabetes.   His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease.  The University of Kansas Lipoprotein-Apheresis Center is the largest in North America for the treatment of Familial Hypercholesterolemia and elevated Lp(a).